AirNexis Therapeutics Launches with $200M Series A to Advance Phase 2 Dual PDE3/4 Inhibitor AN01 for Chronic Obstructive Pulmonary Disease (COPD)
Mentions in press and media 5
| Date | Title | Description |
| 14.01.2026 | AirNexis Therapeutics Secures $200M for Groundbreaking COPD Treatment AN01 | AirNexis Therapeutics emerged, securing $200 million in Series A funding. This substantial capital infusion targets chronic obstructive pulmonary disease (COPD). The company focuses on developing AN01, a novel dual PDE3/4 inhibitor. AN01 is... |
| 12.01.2026 | AirNexis Therapeutics Raises $200M in Series A Funding | AirNexis Therapeutics, a Palo Alto, CA-based clinical stage biotech company developing therapeutics for pulmonary diseases, raised $200M in Series A funding. The round was led by Frazier Life Sciences, with participation from OrbiMed, SR On... |
| 11.01.2026 | AirNexis Therapeutics Launches With $200 Million Series A To Advance Phase 2 Dual PDE3/4 Inhibitor AN01 For COPD | AirNexis Therapeutics has launched as a clinical-stage biotechnology company focused on pulmonary diseases, closing a $200 million Series A financing and securing an in-license to a Phase 2 dual PDE3/4 inhibitor for chronic obstructive pulm... |
| 09.01.2026 | AirNexis takes flight with $200M, links up with China pharma for COPD asset in $955M biobucks deal | AirNexis Therapeutics is taking flight with $200 million and a clinical-stage asset from a Chinese pharma that aims to treat lung disease. Founded by investment firm Frazier Life Sciences, new biotech AirNexis has connected with Haisco Phar... |
| - | AirNexis Therapeutics | - |